Oncology

Exosomes are cell-derived nanovesicles, which are usually 50-150 nm in diameter and are involved in the intercellular transportation of materials....

Microbiome is an emerging player in cancer drug development. Recent research findings elicit varied roles of human gut microbiome, both...

Antibody Drug Conjugates (ADCs) are therapeutic entities with monoclonal antibody (mAb) backbone linked to cytotoxic drugs and are designed to...

Oncolytic Viruses (OVs) based therapies uses natural or genetically modified viruses to specifically infect and lyse cancer cells but does not...

Bispecific (bsAbs) & Multispecific antibodies are a diverse family of antibody constructs that recognize two or more epitopes. These candidates...

Cell Therapies constitutes the largest number of agents in oncology drug development, with currently more than 2000+ Active Cancer Targeting...

. SERINE / THEONINE KINASE INHIBITORS 1. BRAF/MEK/ERK Inhibitors 2. CDK Inhibitors 3. PI3K/AKT/mTOR Inhibitors Check Also KINASE INHIBITORS -...

. NON-RECEPTOR TYROSINE KINASE INHIBITORS 1. Bcr-Abl1 Inhibitors 2. JAK Inhibitors 3. BTK Inhibitors Check Also KINASE INHIBITORS - An...

Protein kinases are the enzymes that catalyzes the transfer of γ-phosphate group from ATP to protein residues containing hydroxyl groups...